Corvus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $34.31 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Corvus Pharmaceuticals Inc had its IPO on 2016-03-23 under the ticker symbol CRVS.
The company operates in the Healthcare sector and Biotechnology industry. Corvus Pharmaceuticals Inc has a staff strength of 28 employees.
Shares of Corvus Pharmaceuticals Inc opened at $0.74 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $0.69 - $0.75, and closed at $0.74.
This is a -0.27% slip from the previous day's closing price.
A total volume of 154,100 shares were traded at the close of the day’s session.
In the last one week, shares of Corvus Pharmaceuticals Inc have increased by +3.52%.
Corvus Pharmaceuticals Inc's Key Ratios
Corvus Pharmaceuticals Inc has a market cap of $34.31 million, indicating a price to book ratio of 0.576 and a price to sales ratio of 0.
In the last 12-months Corvus Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32763000. The EBITDA ratio measures Corvus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Corvus Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -20.74% with a return of equity of -47.96%.
In Q3, Corvus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Corvus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Corvus Pharmaceuticals Inc’s profitability.
Corvus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2654. Its price to sales ratio in the trailing 12-months stood at 0.
Corvus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $80.35 million
- Total Liabilities
- $13.98 million
- Operating Cash Flow
- $3.04 million
- Capital Expenditure
- Dividend Payout Ratio
Corvus Pharmaceuticals Inc ended 2023 with $80.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $80.35 million while shareholder equity stood at $64.68 million.
Corvus Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $13.98 million in other current liabilities, 5000.00 in common stock, $-297872000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.59 million and cash and short-term investments were $49.62 million. The company’s total short-term debt was $1,181,000 while long-term debt stood at $0.
Corvus Pharmaceuticals Inc’s total current assets stands at $51.27 million while long-term investments were $25.91 million and short-term investments were $25.03 million. Its net receivables were $534000.00 compared to accounts payable of $4.23 million and inventory worth $0.
In 2023, Corvus Pharmaceuticals Inc's operating cash flow was $3.04 million while its capital expenditure stood at $265000.
Comparatively, Corvus Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Corvus Pharmaceuticals Inc stock is currently trading at $0.74 per share. It touched a 52-week high of $2.11 and a 52-week low of $2.11. Analysts tracking the stock have a 12-month average target price of $2.83.
Its 50-day moving average was $0.79 and 200-day moving average was $0.9 The short ratio stood at 2.17 indicating a short percent outstanding of 0%.
Around 397.9% of the company’s stock are held by insiders while 4597.7% are held by institutions.
Frequently Asked Questions About Corvus Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.